What's New

Nippon Kayaku announces the final data analysis of a global phase 3 study of NK105, a novel macromolecular micelle encapsulating an anticancer drug, will be presented at the ESMO 2017 Congress

2017/08/31

Tokyo, Japan, August 31, 2017 - Nippon Kayaku Co., Ltd. (Head Office: Tokyo; President: Masanobu Suzuki; hereinafter referred to as “Nippon Kayaku”) announced today that the final data analysis of a global phase 3 study of NK105, a novel macromolecular micelle encapsulating an anticancer drug, will be presented at the ESMO(EUROPIAN SOCIETY FOR MEDICAL ONCOLOGY) 2017 Congress in Madrid, Spain from September 8 to 12, 2017.The abstract is now available on the official website of ESMO.


【Scheduled Presentation at ESMO 2017】
Date and Time: Monday, September 11, 2017
1:15 PM - 2:15 PM (local time)
Abstract Number: 981
Session:Poster Display Session(250P)
Location:Hall 8
https://cslide.ctimeetingtech.com/library/esmo/browse/itinerary/5404/2017-09-11#2Bb5q0hV 

【Reference】
About NK105
NK105 is a novel DDS (Drug Delivery System) formulation encapsulating active ingredient paclitaxel in macromolecular micelles.

[Please direct inquiries regarding this matter to:]
Telephone: +81- 3- 6731- 5237
Public Relations & Investor Relations Division
Nippon Kayaku Co., Ltd.
PageTop
Corporate Vision
Our Business
Corporate Information
Global Netowork
Investor Relations
CSR